5.09
+0.0766(+1.54%)
Currency In USD
| Previous Close | 5.01 |
| Open | 5.17 |
| Day High | 5.25 |
| Day Low | 4.86 |
| 52-Week High | 21.5 |
| 52-Week Low | 4.21 |
| Volume | 265,667 |
| Average Volume | 288,162 |
| Market Cap | 70.18M |
| PE | -1.21 |
| EPS | -4.22 |
| Moving Average 50 Days | 7.24 |
| Moving Average 200 Days | 8.45 |
| Change | 0.08 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $530.41 as of December 26, 2024 at a share price of $5.087. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $255.74 as of December 26, 2024 at a share price of $5.087.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis to Host Year-End Investor Webcast on December 11, 2024
GlobeNewswire Inc.
Nov 25, 2024 1:00 PM GMT
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
GlobeNewswire Inc.
Nov 12, 2024 1:00 PM GMT
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
GlobeNewswire Inc.
Nov 07, 2024 1:00 PM GMT
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer